What You Should Know:
- Sanofi has agreed to acquire Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), for $25.00 per share in cash, representing an equity value of approximately $2.9B.
- The acquisition is a strategic fit for Sanofi at the intersection of the company’s growth in immune-mediated diseases and disease-modifying therapies in areas of high unmet
Read More
type 1 diabetes
The $2.8M Medicine: How Data Can Help Insurers Pay for Life-Changing Therapies Without Breaking The Bank
Advanced medical research has brought us to the point where many serious conditions can potentially be treated and even cured - with people who have essentially faced a lifetime of being incapacitated finally able to conduct normal lives. Many of these treatments are drug-based gene therapies–- but they come with an extremely high price tag. The latest example–and most expensive medication to date– is bluebird bio’s recently-approved $2.8 million gene therapy to treat a rare blood
Read More
At-Home Digital Health Innovations Transforming Diabetes Care
If you’re looking for a silver lining in the COVID-19 dark cloud still enshrouding the world, consider this: The pandemic has turbocharged widespread acceptance of at-home digital health solutions. Forced to function in a world of social distancing, healthcare providers and physicians have quickly discovered how easily telehealth visits, remote patient monitoring (RPM) and digital therapeutics can improve patient care.
Many of these digital health innovations are designed to address
Read More
Early Use of Diabetes Technology Drives Better Patient Outcomes in Kids
A recent study from Stanford found that pediatric patients with rapid access to continuous glucose monitoring soon after a type 1 diabetes diagnosis had healthier blood sugar values than an earlier group of patients who weren’t given the monitors near the time of diagnosis.
The research provides an example of how the healthcare industry is evolving to use technology: It provides more frequent touchpoints with caregivers, makes quality care available to a larger number of patients, and
Read More
Medtronic Launches Initiatives to Address Health Equity for People of Color Living with Diabetes
What You Should Know:
- Medtronic announced its ongoing commitment to health equity for people of color living with diabetes. The company committed investments in partnerships with the American Diabetes Association® (ADA) and T1D Exchange, as well as additional research efforts, to better understand and address these disparities.
New Partnerships and Research Efforts Prioritized Over the Next Three Years to Address Health Disparities
Details of each partnership, as well as additional
Read More
Data-Driven Future: Impact of Machine Learning on Diabetes Management
“Information technology and business are becoming inextricably interwoven. I don't think anybody can talk meaningfully about one without the talking about the other” – Bill Gates wrote this in 1999 and, nowadays, the same can certainly be said about information technology and healthcare.
The ability to collect, analyze, and use data is becoming ubiquitous with many of healthcare’s most exciting advancements. Whether it’s Google’s DeepMind using artificial intelligence (AI) to help
Read More
NIH Funds First Nationwide Rare and Atypical Diabetes Network
What You Should Know:
- NIH awards funding for Rare and Atypical Diabetes
Network, or RADIANT that will seek to discover the cause of
several unusual forms of diabetes.
- RADIANT plans to screen about 2,000 people with unknown
or atypical forms of diabetes that do not fit the common features of type 1 and
type 2 diabetes.
The National Institute of
Health (NIH), announced this week it is funding a nationwide study with The Rare and Atypical Diabetes
Network (RADIANT) that will seek
Read More
FDA Approves Medtronic’s Insulin Pump System for People with Type 1 Diabetes
What You Should Know:
- Medtronic announced the U.S. Food and
Drug Administration (FDA) approval of the MiniMed™ 770G hybrid insulin pump
system with smartphone connectivity and an expanded age indication to patients
with Type 1 diabetes aged 2 and up ― the lowest age indication by the FDA for
an automated insulin pump system.
- The new
MiniMed 770G system comes with the Guardian™ Sensor 34, the MiniMed™ Mobile app
(compatible with both iPhone and Android), and Roche Accu-Chek®
Read More
DreaMed Diabetes Supports Research on Efficacy of Virtual Diabetes Care
What You Should Know:
- DreaMed Diabetes, the developer of personalized, AI-based diabetes management solutions, will participate in a clinical study, led by Jaeb Center for Health Research Foundation, to evaluate the efficacy of virtual treatment for diabetes patients. The research is funded by a grant from The Leona M. and Harry B. Helmsley Charitable Trust.
- DreaMed uses AI-powered technology to seamlessly treat
patients remotely with its virtual diabetes management service by
Read More
DreaMed Launches Virtual Diabetes Clinic to Help Type-1 Diabetics Control Their Condition in Quarantine
What You Should Know:
- As COVID-19 spreads, DreaMed Diabetes unveils virtual diabetes clinic software to treat people with type 1 diabetes remotely.
- The virtual clinic utilizes Dreamed Diabetes’ AI-powered solution, to improve the insulin management treatment by analyzing the patient’s insulin and glucose data in the platform's algorithm and to remotely advise doctors on treatment.
- According to the CDC people with chronic medical conditions, including diabetes, have a higher risk
Read More
